Brief: Simcere Pharmaceutical Says Entered Exclusive License And Collaboration Agreement

Simcere Pharmaceutical

21/11/2023 17:35

Nov 21 (Reuters) - Simcere Pharmaceutical Group Ltd
 2096.HK :
    * ENTERED INTO AN EXCLUSIVE LICENSE AND COLLABORATION
AGREEMENT
WITH CONNECT BIOPHARMA HONGKONG
    * UNDER DEAL, GROUP TO OBTAIN EXCLUSIVE RIGHTS FOR
DEVELOPMENT,
AMONG OTHERS OF ALL INDICATIONS OF RADEMIKIBART IN GREATER CHINA
    * UNDER DEAL, CONNECT BIOPHARMA WILL RECEIVE AN UPFRONT
PAYMENT OF
RMB150 MILLION, AMONG OTHERS

Source text for Eikon:  ID:nHKS85Fjzn 
Further company coverage:  2096.HK 

 ((Reuters.Briefs@thomsonreuters.com;))